New chief at Bellicum; shares up 5% over investor optimism with transition to commercial phase

• Bellicum Pharmaceuticals (NASDAQ:BLCM +5.1%) appoints Rick Fair as President & CEO effective immediately. He succeeds Tom Farrell who will serve as as advisor during the transition.
• Mr. Fair joins the firm from Roche's Genentech where he was SVP, Head of Oncology Global Product Strategy. He will lead the company's advancement into commercial stage anchored by BPX-501.